Promoting early diagnosis and recovering from the COVID-19 pandemic in lung cancer through public awareness campaigns: learning from patient and public insight work.


Journal

BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061

Informations de publication

Date de publication:
11 2021
Historique:
received: 06 10 2021
accepted: 22 10 2021
entrez: 9 11 2021
pubmed: 10 11 2021
medline: 25 11 2021
Statut: ppublish

Résumé

COVID-19 has had a devastating impact on outcomes in lung cancer leading to later stage presentation, less curative treatment and higher mortality. This has amplified the existing problem of late-stage presentation in lung cancer and is a call to arms for a multifaceted strategy to address this, including public awareness campaigns to promote healthcare review in patients with persistent chest symptoms. We report the learning from patient and public insight work from across the North of England exploring the barriers to seeking healthcare review with persistent chest symptoms. Members of the public described how a lack of importance is placed on the common symptoms of lung cancer and a feeling of being unworthy of review by healthcare professionals. They would feel motivated to seek review by dispelling the nihilism of lung cancer and would be able to take action more easily by removing the logistical hassle in the process. We propose a four-pillar framework (validation-endorsement-motivation-action) for developing the content of any public awareness campaigns promoting early diagnosis of lung cancer based on the findings of this comprehensive insight work. All providers and commissioners must work together to overcome the perceived and real barriers to patients with persistent chest symptoms.

Identifiants

pubmed: 34750168
pii: 8/1/e001120
doi: 10.1136/bmjresp-2021-001120
pmc: PMC8576481
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Thorax. 2018 Dec;73(12):1128-1136
pubmed: 29950525
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33737345

Auteurs

Matthew Evison (M)

Lung Cancer & Thoracic Surgery Directorate, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK m.evison@nhs.net.
Lung Pathway Board, Greater Manchester Cancer Alliance, Greater Manchester, UK.

Sarah Taylor (S)

Macmillan GP Lead for Early Diagnosis, Greater Manchester Strategic Health Authority, Manchester, UK.

Seamus Grundy (S)

Respiratory Medicine, Salford Royal NHS Foundation Trust, Salford, UK.

Anna Perkins (A)

Greater Manchester Cancer Communications Team, Greater Manchester Strategic Health Authority, Manchester, Manchester, UK.

Michael Peake (M)

Emeritus Consultant and Honorary Professor of Respiratory Medicine, University of Leicester, Leicester, UK.
Clinical Director, Centre for Cancer Outcomes, North Central and North East London Cancer Alliances, UCLH Cancer Division, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH